Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the EU / 2025-522831-33-00
Authorised, recruitment ended Phase II

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess Efficacy and Safety of Zasocitinib in Moderate to Severe Hidradenitis Suppurativa

2025-522831-33-00 · tracked via the Priya Life Science EU tracker
Sponsor
Takeda Development Center Americas Inc
Sponsor type
Pharmaceutical company
Therapeutic area
Skin and Connective Tissue Diseases
Decision date
06/03/2026
Enrollment target
36
Sites
France, Poland, Netherlands, Germany

Condition studied

Hidradenitis Suppurativa

Investigational medicinal product(s)

ZASOCITINIBMatching Placebo for TAK-279

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male

Primary endpoint

Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16, assessed as proportion of participants who achieve HiSCR75 at Week 16. Hidradenitis Suppurativa Clinical Response 75 is defined as at least a 75% reduction in the total abscess and inflammatory nodule (AN) count with no increase in abscess or draining tunnel count relative to baseline.

Endpoint detail

HiSCR50 at Week 16, assessed as proportion of participants who achieve HiSCR50 at Week 16., Incidence of treatment emergent adverse events (TEAEs) throughout the trial.

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522831-33-00 on CTIS ↗ ← All trials in the EU